FDA must regulate stem cell therapies to mitigate risks to patients and the public
T
Taylor Pike
(S. J. Quinney College of Law, University of Utah)
M
Mary Ann Chirba
(Boston College Law School)
D
Daniel G. Aaron
(S. J. Quinney College of Law, University of Utah)
Article Details
Volume / Issue
Vol. 123, Issue 11
Published
March 17, 2026
ISSN
0027-8424
Publisher
National Academy of Sciences
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
ISSN: 0027-8424 Life Sciences
Authors (3)
T
Taylor Pike
S. J. Quinney College of Law, University of Utah
M
Mary Ann Chirba
Boston College Law School
D
Daniel G. Aaron
S. J. Quinney College of Law, University of Utah
Related Articles from this Journal
Nature’s antivenom: Combinations of conserved rattlesnake serum metalloproteinase inhibitors block the lethal action of viper venoms
Sean B. Carroll, Fiona P. Ukken et al.
Aug 2026
10.1073/pnas.2612168123
Accelerating <i>Campylobacter</i> zoonosis in the Anthropocene
Oakem J. Kyne, Bridget S. Penman et al.
Aug 2026
10.1073/pnas.2609969123
Global threat exposure of islands in a changing world
Clara Marino, Martin Philippe-Lesaffre et al.
Aug 2026
10.1073/pnas.2534106123
A wearable patch for continuous levodopa monitoring in sweat: Towards exertion and power-free pharmacodynamic assessment in Parkinson’s disease
Tamoghna Saha, Muhammad Inam Khan et al.
Aug 2026
10.1073/pnas.2610453123
Energy prioritization and neurometabolic scaling in a social insect brain
Zach N. Coto, Dajia Ye et al.
Aug 2026
10.1073/pnas.2605431123